Wall Street brokerages expect that Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) will report ($0.53) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from ($0.60) to ($0.48). Mersana Therapeutics posted earnings of ($0.59) per share in the same quarter last year, which would indicate a positive year over year growth rate of 10.2%. The business is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Mersana Therapeutics will report full year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.51) to ($1.98). For the next financial year, analysts expect that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.62) to ($1.75). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN – Get Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.28). Mersana Therapeutics had a negative net margin of 8,826.73% and a negative return on equity of 119.10%. During the same quarter last year, the firm earned ($0.50) earnings per share.
Shares of Mersana Therapeutics stock traded down $0.11 on Friday, reaching $3.15. The stock had a trading volume of 53,977 shares, compared to its average volume of 1,724,128. The business’s 50-day moving average price is $3.87 and its two-hundred day moving average price is $5.10. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.28 and a current ratio of 4.28. Mersana Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $15.34. The stock has a market cap of $305.52 million, a P/E ratio of -1.31 and a beta of 2.37.
In other Mersana Therapeutics news, Director Andrew A. F. Hack purchased 135,292 shares of the stock in a transaction on Monday, May 16th. The shares were purchased at an average price of $3.10 per share, with a total value of $419,405.20. Following the acquisition, the director now directly owns 7,872,692 shares of the company’s stock, valued at approximately $24,405,345.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Andrew A. F. Hack purchased 15,599 shares of the stock in a transaction on Monday, May 23rd. The stock was acquired at an average cost of $3.35 per share, for a total transaction of $52,256.65. Following the acquisition, the director now directly owns 8,302,999 shares in the company, valued at $27,815,046.65. The disclosure for this purchase can be found here. Insiders have purchased 1,060,245 shares of company stock worth $4,025,409 in the last ninety days. 5.30% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. bought a new stake in Mersana Therapeutics during the 1st quarter worth approximately $36,000. Quantbot Technologies LP acquired a new stake in shares of Mersana Therapeutics in the 1st quarter valued at approximately $37,000. Virtu Financial LLC acquired a new stake in shares of Mersana Therapeutics in the 1st quarter valued at approximately $53,000. Ensign Peak Advisors Inc acquired a new stake in shares of Mersana Therapeutics in the 4th quarter valued at approximately $56,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Mersana Therapeutics in the 4th quarter valued at approximately $57,000. Institutional investors own 92.74% of the company’s stock.
About Mersana Therapeutics (Get Rating)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Two Retailers, One To Buy And One To Avoid
- It’s Time to Buy into Planet Fitness Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.